Fig. 5
From: Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening
Validation of the screen by knock-out of TBK1 and TRIB2. a Left side: Scatterplot of fold changes for the 1 462 kinase sgRNAs of the HCC-827 cell line at time point day 14 and time point day 21 versus control time point day −10. sgRNAs against TBK1 were annotated by the software Spotfire and visualization was further enhanced by red colored dots. Rigth side: Scatterplot of Q1 and RSA down for the 1 462 kinase sgRNAs of the HCC-827 cell line at time point day 14 versus control time point day −10. b HCC-827 cell line was transduced with a non-targeting sgRNA against GFP and 5 different sgRNAs against TBK1 (TBK1_2 is a sgRNA included in the genome-wide screens while the other 4 were newly designed for this validation). Cell viability was measured 18days after viral transduction. c Equal number of cells transduced with a non-targeting sgRNA against GFP and 5 different sgRNAs against TBK1. Crystal violet staining was performed after 28 days. d-e Same as in a-c but CHP212 cells were used with the candidate TRIB2